Horizon Discovery Group plc (LSE: HZD) ("Horizon"),[2] is a gene editing company that designs and engineers genetically modified cells and then applies them in research and clinical applications in human health.
Horizon offers human disease models and reagents derived from genetically-engineered cells that its customers may use to gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted at these genetic drivers; and develop companion diagnostics that predict patient response in the clinic.
Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange’s AIM market under the ticker “HZD”.
Horizon signed agreements in December 2019 and January 2020 with Mammoth Biosciences to combine Mammoth's intellectual property in CRISPR with Horizon's expertise in Chinese hamster ovary cells.[3]
Perkin-Elmer acquired Horizon Discovery for $383 million (£296 million) in November 2020.[4] Due to Perkin-Elmer split, since May 2023 Horizon Discovery is now part of Revvity, Inc.[5]